Our data showed that at a median recurrence PSA value <1 ng/dl the risk of choline-negative PET/CT scan increased, thus confirming the higher sensitivity of PSMA PET in relapsed prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.